查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1603845

肺炎鏈球菌疫苗的市場至2030年的預測：按產品類型、疫苗類型、年齡層、分銷管道、最終用戶和地區的全球分析

Pneumococcal Vaccine Market Forecasts to 2030 - Global Analysis By Product Type, Vaccine Type, Age Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的資料，2024年全球肺炎鏈球菌疫苗市場規模為88億美元，預計2030年將達到130.8億美元，預測期內年複合成長率為6.8%。

肺炎鏈球菌疫苗接種是一種預防由肺炎鏈球菌引起的感染疾病的疫苗，這種感染會引起敗血症、腦膜炎和肺炎等嚴重症狀。兩種主要類型是肺炎鏈球菌結合疫苗（PCV）如PCV13和肺炎鏈球菌多醣體疫苗（PPSV）如PPSV23。這些疫苗接種對於幼兒、老年人和免疫力較弱的人等弱勢群體尤其重要。這些疫苗的作用是提高免疫系統識別和攻擊肺炎球菌的能力。

根據聯合國國際兒童緊急基金會（UNICEF）2023年11月發布的資料，全球整體每天約有2,000名兒童受到肺炎影響。

肺炎鏈球菌疾病的盛行率增加

對肺炎鏈球菌疫苗的需求主要是由肺炎球菌疾病（包括腦膜炎和肺炎）發生率的上升所推動的。這些感染疾病給全球健康帶來了巨大的負擔，特別是當它們影響幼兒和老年人時。有效免疫接種的可用性以及人們對肺炎鏈球菌感染相關嚴重健康風險的認知不斷提高，推動市場擴張。隨著全球醫療保健系統更加重視公共衛生宣傳活動和預防措施，對肺炎鏈球菌疫苗接種的需求預計將逐漸增加。

供應鏈中斷

肺炎鏈球菌疫苗產業受到生產和供應鏈中斷的嚴重影響，這可能導致疫苗短缺、疫苗接種計劃推遲並危及公共衛生工作。原料短缺或嚴格的品管要求等製造問題會擾亂生產，導致此類中斷。此外，疫苗的及時分發將受到後勤挑戰的阻礙，包括低溫運輸基礎設施不足、運輸延誤和地緣政治因素，特別是在農村和低收入地區。

提高認知和疫苗接種計劃

意識和免疫計劃推動了肺炎球菌疫苗市場的發展，因為世界衛生組織（WHO）和聯合國兒童基金會等組織的政府舉措和宣傳活動目的是教育公眾了解肺炎球菌感染的危險，這是一個重要因素。為了鼓勵及早接種疫苗並阻止疾病傳播，這些舉措主要針對老年人和新生兒等高風險族群。廣泛的免疫宣傳活動日益增加免疫接種的機會，促進全球公共衛生成果，並促進整體市場成長，特別是在低收入和中等收入國家。

疫苗接種費用高

肺炎鏈球菌疫苗接種的高昂費用是低收入者和醫療保健預算有限的國家獲得疫苗接種的主要障礙。 PPSV23 和 Prevnal 13 等疫苗需要先進的製造技術來生產，這使其變得昂貴。儘管一些公共衛生舉措免費或以大幅折扣提供疫苗，但財政限制仍可能阻礙普遍接種。這種成本障礙在低度開發國家尤其成問題，許多人由於自付費用而迴避疫苗接種，影響了整體疫苗接種覆蓋率並增加了疾病風險。

COVID-19 的影響

肺炎鏈球菌疫苗市場受到COVID-19大流行的顯著影響，機會與挑戰並存。最初，免疫計劃因醫療服務和供應鏈中斷而受到阻礙，導致疫苗接種計劃延遲。然而，由於大流行，肺炎球菌疫苗的需求量很大，這提高了人們對呼吸道疾病的認知並擴大了公共衛生宣傳活動。預防肺炎的需要，特別是針對弱勢族群的肺炎，促使各國政府加強了疫苗接種力道。因此，隨著醫療保健系統的調整以及肺炎球菌疫苗接種與 COVID-19舉措同等重要，市場預計將擴大。

預計兒科領域在預測期內將是最大的。

據估計，兒科市場是最大的。新生兒和幼兒中肺炎球菌疾病（包括腦膜炎和肺炎）的高盛行率構成了重大的健康風險。由於強調兒童疫苗重要性的政府措施和公共衛生計劃，需求不斷增加。有效的肺炎球菌疫苗的可用性以及家長對免疫接種益處的了解的增加進一步推動了小兒科領域的市場擴張。

在預測期內，醫院/診所產業預計年複合成長率最高

預計醫院和診所產業在預測期內的年複合成長率最高。這些醫療保健中心對於為弱勢群體，特別是幼兒、老年人和免疫力較弱的人提供疫苗接種非常重要。鼓勵衛生保健專業人員透過政府促進免疫計畫和疫苗接種償付政策提供肺炎球菌疫苗。此外，肺炎鏈球菌感染的日益普及以及對預防保健的重視也增加了診所和醫院對疫苗的需求。

佔比最大的地區：

由於在目的是降低兒童死亡率的政府免疫計劃的支持下，人們對肺炎鏈球菌感染的認知不斷提高，預計亞太地區將在預測期內佔據最大的市場佔有率。都市化進程的加速和衛生基礎設施的改善也促進了疫苗向不同人群的獲取和分發。此外，不斷成長的老年人口（特別容易受到肺炎鏈球菌感染）也增加了需求。與全球衛生組織的合作夥伴關係和津貼進一步提高疫苗接種率，而印度和中國公司的本地生產努力幫助使疫苗變得更便宜和容易獲得。

年複合成長率最高的地區：

由於對免疫接種益處的高度認知、政府強力的醫療保健計劃以及保險系統全面的疫苗覆蓋範圍，預計北美在預測期內的年複合成長率最高。發達的醫療保健基礎設施使人們能夠廣泛獲得疫苗接種，特別是對於兒童、老年人和慢性疾病患者等弱勢群體。主要製藥公司的持續研究和開發也支持推出具有更廣泛血清型覆蓋範圍的先進疫苗。此外，公共衛生工作和常規疫苗接種建議也促進了該地區疫苗的高接種率。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之1：

  • 公司簡介
    • 其他市場公司的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球肺炎鏈球菌疫苗市場：依產品類型

  • Prevnar 13 (PCV13)
  • Pneumovax 23 (PPSV23)
  • Vaxneuvance (PCV15)
  • 新產品和研發線產品
  • Synflorix
  • Pneumosil
  • 其他產品類型

第6章 全球肺炎鏈球菌疫苗市場：依疫苗類型

  • 肺炎鏈球菌結合疫苗（PCV）
  • 肺炎鏈球菌多醣體疫苗（PPSV）

第7章 全球肺炎鏈球菌疫苗市場：依年齡層別

  • 兒科
  • 成人
  • 老年

第8章 全球肺炎鏈球菌疫苗市場：依通路分類

  • 銷售合作公司
  • 非政府組織（NGO）
  • 政府機關

第9章 全球肺炎鏈球菌疫苗市場：依最終用戶分類

  • 醫院和診所
  • 公共衛生機構與免疫規劃
  • 門診手術中心
  • 家庭健康環境
  • 零售藥房
  • 網路藥房
  • 其他最終用戶

第10章 全球肺炎鏈球菌疫苗市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 公司概況

  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bharat Biotech
  • SK Bioscience
  • Johnson & Johnson
  • Biological E. Limited
  • Sinovac Biotech Ltd.
  • LG Chem Ltd.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Indian Immunologicals Ltd.
  • Novartis AG
Product Code: SMRC27867

According to Stratistics MRC, the Global Pneumococcal Vaccine Market is accounted for $8.80 billion in 2024 and is expected to reach $13.08 billion by 2030 growing at a CAGR of 6.8% during the forecast period. A pneumococcal vaccination is a prophylactic injection intended to guard against infections brought on by the Streptococcus pneumoniae bacterium, which can result in grave conditions like sepsis, meningitis, and pneumonia. Pneumococcal conjugate vaccines (PCV), such as PCV13, and pneumococcal polysaccharide vaccines (PPSV), such as PPSV23, are the two primary varieties. For vulnerable groups, particularly small children, the elderly, and those with compromised immune systems, these vaccinations are essential. They function by boosting the immune system's capacity to identify and attack pneumococcal bacteria.

According to the data published by the UN International Children's Emergency Fund (UNICEF) in November 2023, around 2,000 children were globally affected by pneumonia on a daily basis.

Market Dynamics:

Driver:

Growing prevalence of pneumococcal diseases

Pneumococcal vaccination demand is largely driven by the rising incidence of pneumococcal illnesses including meningitis and pneumonia. These infections are a major worldwide health burden, especially when they affect young children and the elderly. The availability of efficient vaccinations and growing awareness of the severe health risks linked to pneumococcal infections are driving market expansion. Pneumococcal vaccination demand is expected to increase gradually as global healthcare systems place a greater emphasis on public health campaigns and preventive measures.

Restraint:

Disruptions in supply chain

The pneumococcal vaccine industry is greatly impacted by production and supply chain disruptions, which may result in vaccine shortages, postponed vaccination schedules, and jeopardized public health initiatives. Manufacturing issues like scarce raw materials or strict quality control requirements that impede output can cause these interruptions. Additionally, timely vaccination distribution is hampered by logistical problems, especially in rural and low-income areas, such as poor cold chain infrastructure, transportation delays, or geopolitical factors.

Opportunity:

Increasing awareness and immunization programs

As government initiatives and campaigns by organizations like the World Health Organization (WHO) and UNICEF try to educate the public on the hazards of pneumococcal infections, rising awareness and immunization programs are important factors driving the pneumococcal vaccine market. To encourage early immunization and stop the spread of disease, these initiatives focus on high-risk populations, such as the elderly and newborns. Widespread vaccination campaigns increase access to vaccinations, which boosts global public health outcomes and contributes to market growth overall, particularly in low- and middle-income nations.

Threat:

High cost of vaccination

Pneumococcal vaccination's high price is a major barrier to availability for low-income groups and in nations with tight healthcare budgets. Advanced manufacturing techniques are needed to produce vaccines like PPSV23 and Prevnar 13, which raises the price. Even while some public health initiatives offer free or heavily discounted vaccines, financial constraints may still prevent universal availability. This cost barrier is particularly problematic in underdeveloped nations, as many people are discouraged from getting vaccinated due to the high out-of-pocket expenses, which affects overall vaccination rates and raises the risk of disease.

Covid-19 Impact

The pneumococcal vaccination market was greatly impacted by the COVID-19 pandemic, which carried with it both opportunities and challenges. Initially, vaccination programs were hampered by disruptions in healthcare services and supply chains, which resulted in delays in immunization schedules. Pneumococcal vaccinations, however, are in high demand as a result of the pandemic's increased awareness of respiratory illnesses and larger public health campaigns. The necessity of preventing pneumonia, especially in susceptible groups, prompted governments to step up immunization initiatives. As a result, the market is anticipated to expand as healthcare systems adjust and give pneumococcal vaccination equal weight with COVID-19 initiatives.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to be the largest. Significant health risks are presented by the high prevalence of pneumococcal illnesses in newborns and young children, including meningitis and pneumonia. Demand is being increased by government initiatives and public health programs that highlight the significance of childhood vaccines. Further propelling market expansions in the pediatric sector are the availability of efficacious pneumococcal vaccines and parents' growing knowledge of the advantages of immunization.

The hospitals and clinics segment is expected to have the highest CAGR during the forecast period

The hospitals and clinics segment is anticipated to witness the highest CAGR during the forecast period. These healthcare centers are essential for delivering vaccinations, especially to susceptible groups including young children, the elderly, and people with weakened immune systems. Healthcare professionals are encouraged to offer pneumococcal vaccines by government programs that promote immunization and reimbursement policies for vaccine administration. Additionally, the growing prevalence of pneumococcal infections and the emphasis on preventative healthcare are fuelling the need for vaccines in clinics and hospitals.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rising awareness of pneumococcal diseases, supported by government-backed immunization programs aimed at reducing child mortality rates. Increasing urbanization and improved healthcare infrastructure also facilitate vaccine access and distribution across diverse populations. Additionally, a growing geriatric population, particularly vulnerable to pneumococcal infections, amplifies demand. Partnerships with global health organizations and subsidies further boost vaccination rates, while local production efforts by companies in India and China help make vaccines more affordable and accessible.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, owing to high awareness of immunization benefits, robust government healthcare programs, and comprehensive vaccine coverage under insurance plans. The established healthcare infrastructure enables wide access to vaccination, particularly for vulnerable groups like children, the elderly, and those with chronic illnesses. Ongoing research and development by key pharmaceutical players also support the introduction of advanced vaccines with broader serotype coverage. Additionally, public health initiatives and routine vaccination recommendations contribute to high vaccine adoption rates across the region.

Key players in the market

Some of the key players profiled in the Pneumococcal Vaccine Market include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Astellas Pharma Inc., AstraZeneca, Bharat Biotech, SK Bioscience, Johnson & Johnson, Biological E. Limited, Sinovac Biotech Ltd., LG Chem Ltd., Panacea Biotec Ltd., Walvax Biotechnology Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Indian Immunologicals Ltd., and Novartis AG.

Key Developments:

In April 2024, Merck presented the results of the phase 3 clinical trial STRIDE-10 for an investigational 21-valent pneumococcal conjugate vaccine developed for adults.

In January 2024, Pfizer Inc. received marketing authorization from the Committee of Medicinal Products designed for Human Use (CHMP) of the European Medicines Agency (EMA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC).

In April 2023, Pfizer Inc. received FDA approval for Prevnar 20 to prevent Invasive Pneumococcal Disease (IPD) in infants.

Product Types Covered:

  • Prevnar 13 (PCV13)
  • Pneumovax 23 (PPSV23)
  • Vaxneuvance (PCV15)
  • New and Pipeline Products
  • Synflorix
  • Pneumosil
  • Other Product Types

Vaccine Types Covered:

  • Pneumococcal Conjugate Vaccine (PCV)
  • Pneumococcal Polysaccharide Vaccine (PPSV)

Age Groups Covered:

  • Pediatric
  • Adult
  • Geriatric

Distribution Channels Covered:

  • Distribution Partner Companies
  • Non-Governmental Organizations (NGOs)
  • Government Authorities

End Users Covered:

  • Hospitals and Clinics
  • Public Health Agencies and Immunization Programs
  • Ambulatory Surgical Centers
  • Home Healthcare Settings
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pneumococcal Vaccine Market, By Product Type

  • 5.1 Introduction
  • 5.2 Prevnar 13 (PCV13)
  • 5.3 Pneumovax 23 (PPSV23)
  • 5.4 Vaxneuvance (PCV15)
  • 5.5 New and Pipeline Products
  • 5.6 Synflorix
  • 5.7 Pneumosil
  • 5.8 Other Product Types

6 Global Pneumococcal Vaccine Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Pneumococcal Conjugate Vaccine (PCV)
  • 6.3 Pneumococcal Polysaccharide Vaccine (PPSV)

7 Global Pneumococcal Vaccine Market, By Age Group

  • 7.1 Introduction
  • 7.2 Pediatric
  • 7.3 Adult
  • 7.4 Geriatric

8 Global Pneumococcal Vaccine Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Distribution Partner Companies
  • 8.3 Non-Governmental Organizations (NGOs)
  • 8.4 Government Authorities

9 Global Pneumococcal Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Public Health Agencies and Immunization Programs
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Home Healthcare Settings
  • 9.6 Retail Pharmacies
  • 9.7 Online Pharmacies
  • 9.8 Other End Users

10 Global Pneumococcal Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Merck & Co., Inc.
  • 12.3 Sanofi S.A.
  • 12.4 GlaxoSmithKline plc
  • 12.5 Serum Institute of India Pvt. Ltd.
  • 12.6 Astellas Pharma Inc.
  • 12.7 AstraZeneca
  • 12.8 Bharat Biotech
  • 12.9 SK Bioscience
  • 12.10 Johnson & Johnson
  • 12.11 Biological E. Limited
  • 12.12 Sinovac Biotech Ltd.
  • 12.13 LG Chem Ltd.
  • 12.14 Panacea Biotec Ltd.
  • 12.15 Walvax Biotechnology Co., Ltd.
  • 12.16 Mitsubishi Tanabe Pharma Corporation
  • 12.17 Indian Immunologicals Ltd.
  • 12.18 Novartis AG

List of Tables

  • Table 1 Global Pneumococcal Vaccine Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Pneumococcal Vaccine Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Pneumococcal Vaccine Market Outlook, By Prevnar 13 (PCV13) (2022-2030) ($MN)
  • Table 4 Global Pneumococcal Vaccine Market Outlook, By Pneumovax 23 (PPSV23) (2022-2030) ($MN)
  • Table 5 Global Pneumococcal Vaccine Market Outlook, By Vaxneuvance (PCV15) (2022-2030) ($MN)
  • Table 6 Global Pneumococcal Vaccine Market Outlook, By New and Pipeline Products (2022-2030) ($MN)
  • Table 7 Global Pneumococcal Vaccine Market Outlook, By Synflorix (2022-2030) ($MN)
  • Table 8 Global Pneumococcal Vaccine Market Outlook, By Pneumosil (2022-2030) ($MN)
  • Table 9 Global Pneumococcal Vaccine Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 10 Global Pneumococcal Vaccine Market Outlook, By Vaccine Type (2022-2030) ($MN)
  • Table 11 Global Pneumococcal Vaccine Market Outlook, By Pneumococcal Conjugate Vaccine (PCV) (2022-2030) ($MN)
  • Table 12 Global Pneumococcal Vaccine Market Outlook, By Pneumococcal Polysaccharide Vaccine (PPSV) (2022-2030) ($MN)
  • Table 13 Global Pneumococcal Vaccine Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 14 Global Pneumococcal Vaccine Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 15 Global Pneumococcal Vaccine Market Outlook, By Adult (2022-2030) ($MN)
  • Table 16 Global Pneumococcal Vaccine Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 17 Global Pneumococcal Vaccine Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 18 Global Pneumococcal Vaccine Market Outlook, By Distribution Partner Companies (2022-2030) ($MN)
  • Table 19 Global Pneumococcal Vaccine Market Outlook, By Non-Governmental Organizations (NGOs) (2022-2030) ($MN)
  • Table 20 Global Pneumococcal Vaccine Market Outlook, By Government Authorities (2022-2030) ($MN)
  • Table 21 Global Pneumococcal Vaccine Market Outlook, By End User (2022-2030) ($MN)
  • Table 22 Global Pneumococcal Vaccine Market Outlook, By Hospitals and Clinics (2022-2030) ($MN)
  • Table 23 Global Pneumococcal Vaccine Market Outlook, By Public Health Agencies and Immunization Programs (2022-2030) ($MN)
  • Table 24 Global Pneumococcal Vaccine Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 25 Global Pneumococcal Vaccine Market Outlook, By Home Healthcare Settings (2022-2030) ($MN)
  • Table 26 Global Pneumococcal Vaccine Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 27 Global Pneumococcal Vaccine Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 28 Global Pneumococcal Vaccine Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.